Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.

[1]  Vasilis Ntziachristos,et al.  Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo , 2006, Circulation.

[2]  Martin Bendszus,et al.  Inflammation and Atherosclerosis: Novel Insights Into Plaque Formation and Destabilization , 2006, Stroke.

[3]  Hong Chen.  Cellular inflammatory responses: novel insights for obesity and insulin resistance. , 2006, Pharmacological research.

[4]  A. Gotto.  Statins, cardiovascular disease, and drug safety. , 2006, The American journal of cardiology.

[5]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[6]  M. Endres.  Statins: potential new indications in inflammatory conditions. , 2006, Atherosclerosis. Supplements.

[7]  E. Kılıç,et al.  Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2 , 2005, Neuroscience.

[8]  M. Endres.  Statins and Stroke , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  R. de Caterina,et al.  Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. , 2005, Cardiovascular Research.

[10]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[11]  M. Wolzt,et al.  Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo , 2005, Circulation.

[12]  S. Konstantinides,et al.  Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury , 2004, Thrombosis and Haemostasis.

[13]  R. Paoletti,et al.  Statins effect on smooth muscle cell proliferation. , 2004, Seminars in vascular medicine.

[14]  Robert Kleemann,et al.  Effect of Low Dose Atorvastatin Versus Diet-Induced Cholesterol Lowering on Atherosclerotic Lesion Progression and Inflammation in Apolipoprotein E*3–Leiden Transgenic Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[15]  V. Fuster,et al.  Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. , 2004, European heart journal.

[16]  J. Davignon.  Beneficial Cardiovascular Pleiotropic Effects of Statins , 2004, Circulation.

[17]  Robert Kleemann,et al.  Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol–Lowering Effect in APOE*3-Leiden Transgenic Mice: Evidence for Antiinflammatory Effects of Rosuvastatin , 2003, Circulation.

[18]  M. Rosenfeld,et al.  Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. , 2003, Atherosclerosis.

[19]  A. Gotto.  Safety and statin therapy: reconsidering the risks and benefits. , 2003, Archives of internal medicine.

[20]  Brian J. Bennett,et al.  Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[21]  Paul D. Martin,et al.  No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG‐CoA Reductase Inhibitor , 2002, Journal of clinical pharmacology.

[22]  Steven P Jones,et al.  Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. , 2002, Journal of the American College of Cardiology.

[23]  P. Libby,et al.  Statins Reduce Inflammation in Atheroma of Nonhuman Primates Independent of Effects on Serum Cholesterol , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[24]  M. Endres,et al.  Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice , 2002, Brain Research.

[25]  R. Vergona,et al.  Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. , 2002, Atherosclerosis.

[26]  S. Blankenberg,et al.  Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. , 2002, The American journal of cardiology.

[27]  E. Tremoli,et al.  Fluvastatin Reduces Tissue Factor Expression and Macrophage Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits in the Absence of Lipid Lowering , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[28]  S. Janciauskiene,et al.  Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. , 2002, Pharmacological research.

[29]  R. de Caterina,et al.  Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. , 2001, Cardiovascular research.

[30]  A. M. Lefer,et al.  A new HMG‐CoA reductase inhibitor, rosuvastatin, exerts anti‐inflammatory effects on the microvascular endothelium: the role of mevalonic acid , 2001, British journal of pharmacology.

[31]  Joerg Kallen,et al.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.

[32]  Y. Chao,et al.  Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[33]  Y. Chao,et al.  Infectious Agents Are Not Necessary for Murine Atherogenesis , 2000, The Journal of experimental medicine.

[34]  P. Libby.  Changing concepts of atherogenesis , 2000, Journal of internal medicine.

[35]  F. Bernini,et al.  Non-lipid-related effects of statins , 2000, Annals of medicine.

[36]  R. Ross,et al.  Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[37]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[38]  V. Fuster,et al.  Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. , 1997, Circulation.

[39]  E. Tremoli,et al.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[40]  P. Milos,et al.  Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Taylor,et al.  Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. , 1995, The Journal of clinical investigation.

[42]  V. Fuster,et al.  Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.

[43]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[44]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[45]  N. Maeda,et al.  Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. Shimano,et al.  Macrophage colony stimulating factor prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. , 1992, Atherosclerosis.

[47]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[48]  R. Williams,et al.  Quantitative assessment of atherosclerotic lesions in mice. , 1987, Atherosclerosis.

[49]  M. Brown,et al.  Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. , 1980, The Journal of clinical investigation.

[50]  P. Ridker,et al.  C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. , 2002, Preventive cardiology.

[51]  K. V. van Dijk,et al.  Effect of macrophage-derived mouse ApoE, human ApoE3-Leiden, and human ApoE2 (Arg158-->Cys) on cholesterol levels and atherosclerosis in ApoE-deficient mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[52]  J. Breslow,et al.  Apolipoprotein E and the apolipoprotein E-deficient mouse. , 1995, Annual review of nutrition.

[53]  R. Ross,et al.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[54]  N. Maeda,et al.  Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[55]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.

[56]  A. Gown,et al.  Fatty streak expansion and maturation in Watanabe Heritable Hyperlipemic and comparably hypercholesterolemic fat-fed rabbits. , 1987, Arteriosclerosis.